Evaxion A/S filings document a foreign private issuer that furnishes Form 6-K reports for business updates, financial results, clinical and preclinical vaccine-program disclosures, and governance actions. Recent reports describe AI-Immunology™-powered vaccine development, EVX-01 personalized cancer vaccine data in advanced melanoma, platform work in glioblastoma, and infectious disease vaccine design concepts.
The filing record also includes annual general meeting results, approval of the audited annual report, board and auditor elections, leadership-role disclosures, and incorporation of Form 6-K reports by reference into Form S-8, Form F-1, and Form F-3 registration statements. These documents frame Evaxion’s capital-market disclosures around pipeline development, corporate governance, securities registrations, and recurring operating updates.
Evaxion A/S (EVAX) reported that all patients at three-year follow-up in its Phase 2 trial of personalized cancer vaccine EVX-01 for advanced melanoma maintained clinical responses observed at two years, with no tumor progression observed. Patients received EVX-01 alone in the third year, after receiving it with KEYTRUDA (pembrolizumab) during the first two years.
The earlier two-year results included a 75% Objective Response Rate, with 25% of patients obtaining a complete response. At two years, 92% of patients were still responding, with no relapses observed; tumor reduction was seen in 15 of 16 enrolled patients, and 86% of vaccine neoantigens generated potent specific T-cell responses.
Evaxion A/S (EVAX) said it will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting in Phoenix from November 4 through November 8, 2026. The data are from a Phase 2 trial of EVX-01 plus pembrolizumab in patients with advanced melanoma and will be presented in both an oral presentation and a poster. They will address systemic immunomodulatory effects beyond vaccine-specific T-cell responses.
Evaxion said complete three-year clinical data will be presented at ESMO on October 24, 2026. Patients received EVX-01 as stand-alone therapy in the third year. Previously reported two-year results included a 75% objective response rate (12 of 16 patients), four complete responses, and 92% of patients still responding at two-year follow-up; no relapses were observed.
Evaxion A/S (EVAX), a clinical-stage TechBio company, reports that it has begun applying its proprietary AI-Immunology™ platform to autoimmune diseases, expanding its therapeutic focus beyond cancer and infectious diseases. The company is experimentally testing two AI-Immunology™-based treatment concepts for autoimmune conditions.
The first is a tolerogenic vaccine concept using T‑cell epitopes with immune modulators to direct the immune system toward tolerance. The second is an autoantibody binder concept, using an antigen construct designed to capture disease-driving autoantibodies. Initial experimental data from these programs are expected to be presented at the PEGS Europe summit in Lisbon on November 18, 2026.
Evaxion A/S (EVAX) reports that between August 19 and August 21, 2026, it sold 681,268 American Depositary Shares (ADSs) in an at-the-market offering under its Capital Demand Sales Agreement with JonesTrading at an average price of $3.1987 per ADS. After fees and expenses, net proceeds to the company were $2,113,767.
Each ADS represents 50 ordinary shares. In connection with these sales, Evaxion registered an aggregate share capital increase of nominal DKK 8,515,850, bringing total share capital to nominal DKK 112,768,539, effective August 24, 2026. The company amended its Articles of Association to reflect the increased share capital.
Evaxion A/S (EVAX), a clinical-stage TechBio company using its AI-Immunology™ platform to develop cancer and infectious disease vaccines, reported a second-quarter 2026 net loss of $3.7 million, compared with $4.8 million a year earlier. R&D expenses were $2.3 million and G&A expenses $1.5 million, reflecting lower capital markets-related costs versus 2025. Cash and cash equivalents were $14.0 million as of June 30, 2026, supporting a stated cash runway into the second half of 2027, while total equity was $9.5 million.
Evaxion highlighted pipeline progress, including upcoming three-year phase 2 data for personalized melanoma vaccine EVX-01, preclinical data and planned clinical filing for AML vaccine EVX-04, new glioblastoma program EVX-05, and infectious disease candidate EVX-V1 for CMV. The company also noted multiple ongoing partnership discussions and recognition of AI-Immunology™ through the 2026 Prix Galien UK Award for Best digital health solution.
Evaxion A/S (EVAX) reported unaudited Q2 2026 results showing continued operating losses and cash usage while affirming a multiyear funding runway. For the six months ended June 30, 2026, the company reported no revenue, versus a small grant-related revenue of $37 thousand in the prior-year period.
Research and development expenses were $4.6 million, slightly above $4.3 million a year earlier, while general and administrative expenses declined to $3.0 million from $3.9 million, mainly due to lower capital market transaction costs. Net loss for the six months widened to $7.4 million from $6.4 million, and total comprehensive loss was $7.7 million. Cash and cash equivalents were $14.0 million at June 30, 2026, down from $23.2 million at December 31, 2025, with net cash used in operating activities of $8.3 million in the half-year. Total equity decreased to $9.5 million from $17.0 million, while total borrowings were $5.3 million. Management and the board state they expect existing resources to finance operations into the second half of 2027, and they highlight additional capacity under an at-the-market program and recent AI-Immunology™ platform and pipeline progress.
Evaxion A/S reports a strategic refocus of its oncology R&D pipeline by introducing EVX-05, an AI-designed, off-the-shelf therapeutic vaccine program targeting glioblastoma, while discontinuing the EVX-03 program as part of portfolio management. EVX-05 uses the company’s AI-Immunology™ platform to identify conserved endogenous retrovirus (ERV)-derived antigens shared across glioblastoma patients.
Evaxion is collaborating with Duke University School of Medicine, where Professor Mustafa Khasraw’s team is expected to conduct initial clinical testing, potentially in a cost-efficient phase 1 trial. Management states that EVX-05 development costs fit within existing budgets and that the company’s cash runway continues into the second half of 2027. A conference call on August 20, 2026 will cover Q2 2026 results and the new program.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines, plans to provide a business update and report its second quarter 2026 financial results on August 20, 2026 before the opening of the Nasdaq CM.
Executive management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Participants must register in advance to receive dial-in details and may also access a live webcast, with a recording available on the company’s website.
Evaxion A/S states that it will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma at the ESMO Congress 2026 in Madrid. The third-year extension includes EVX-01 as stand-alone therapy without anti-PD-1 combination.
The company highlights previously reported two-year results in 16 patients: an Objective Response Rate of 75% with 12 objective responses and 4 complete responses; 92% of patients were still responding at two years with no relapses, tumor reduction in 15 patients, and EVX-01–induced immune responses in all patients, with 86% of targeted neoantigens generating potent T-cell responses.
Evaxion A/S reports new preclinical data for its cytomegalovirus (CMV) vaccine program EVX‑V1, developed using its AI‑Immunology™ platform. The data, presented in a poster at the International Herpesvirus Workshop 2026 in Montreal, show that novel AI‑discovered T‑cell epitopes may improve control of acute CMV infection, latency and viral reactivation in CMV‑infected mice.
These findings complement earlier preclinical results where novel B‑cell antigens reduced viral infection and optimized structural B‑cell antigens mediated superior viral neutralization. EVX‑V1 combines these novel antigens with an AI‑optimized pre‑fusion glycoprotein B (gB) antigen, aiming for a broader, multi‑targeted immune response and a potentially more protective CMV vaccine concept that could extend to other herpesviruses.